Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Regional Anaesthesia for Disaster Injuries
NCT02698228Phase 4Withdrawn
- Sponsor
- Illumina
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, triple-blind trial of levobupivacaine in lower extremity injury and bone fracture (3 arms), sponsored by Illumina. Primary endpoint: Summed Pain Intensity Difference at 24 hours. Planned start Mar 2016; status: withdrawn.
02
Drugs
levobupivacaine
03
Conditions
lower extremity injurybone fracture
Beyond the preview
Go deeper on NCT02698228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698228.